XML 28 R6.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Changes in Redeemable Common Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Series A Common Stock
Series B Common Stock
Conversion of Redeemable Common Stock
Conversion of Common Stock Upon Shareholder Election and Vesting of Certain Equity Awards
Conversion of Common Stock Upon Exercise of Greenshoe Option
Common Stock
Series A Common Stock
Common Stock
Series B Common Stock
Common Stock
Conversion of Redeemable Common Stock
Series B Common Stock
Common Stock
Conversion of Common Stock Upon Shareholder Election and Vesting of Certain Equity Awards
Series A Common Stock
Common Stock
Conversion of Common Stock Upon Shareholder Election and Vesting of Certain Equity Awards
Series B Common Stock
Common Stock
Conversion of Common Stock Upon Exercise of Greenshoe Option
Series A Common Stock
Common Stock
Conversion of Common Stock Upon Exercise of Greenshoe Option
Series B Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Conversion of Redeemable Common Stock
Accumulated Deficit
Accumulated Deficit
Conversion of Redeemable Common Stock
Beginning balance (in shares) at Dec. 31, 2022 64,046,223                                
Beginning balance at Dec. 31, 2022 $ 1,531,853                                
Redeemable Common Stock                                  
Accretion of redeemable common stock to redemption value $ 399,685                                
Reclassification of redeemable common stock to Series B common stock (in shares) (64,046,223)                                
Reclassification of redeemable common stock to Series B common stock $ (1,931,538)                                
Ending balance (in shares) at Dec. 31, 2023 0                                
Ending balance at Dec. 31, 2023 $ 0                                
Beginning balance (in shares) at Dec. 31, 2022             0 170,855,313                  
Beginning balance at Dec. 31, 2022 (1,036,183)           $ 0 $ 171           $ 1,249,065   $ (2,285,419)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of common stock upon exercise of common stock options (in shares)               2,419,308                  
Issuance of common stock upon exercise of common stock options 4,144             $ 3           4,141      
Issuance of common stock upon vesting of restricted stock units (in shares)             27,250 7,179,136                  
Issuance of common stock upon vesting of restricted stock units 0             $ 7           (7)      
Accretion of redeemable common stock to redemption value (399,685)                         (399,685)      
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)               6,051,285                  
Issuance of common stock upon exercise of collaboration agreement warrants 62             $ 6           56      
Vested warrants related to the collaboration agreement 142,326                         142,326      
Stock-based compensation expense 342,148                         342,148      
Vesting of restricted common stock (in shares)               26,795                  
Vesting of restricted common stock 75                         75      
Issuance of Common Stock in Connection with Initial Public Offering Net of Underwriters' Discounts, Commissions and Offering Costs (in shares)             11,507,693                    
Issuance of Common Stock in Connection with Initial Public Offering Net of Underwriters' Discounts, Commissions and Offering Costs 320,096           $ 12             320,084      
Shares withheld for tax withholding upon vesting of restricted stock units (in shares)             (11,874) (2,735,286)                  
Shares withheld for tax withholding upon vesting of restricted stock units (81,511)           $ (1) $ (2)           (81,508)      
Conversion of common stock (in shares)                 64,046,223 27,548,447 (27,548,447) 1,770,318 (1,770,318)        
Reclassification of redeemable common stock to Series B common stock       $ 1,931,538         $ 64           $ 136,865   $ 1,794,609
Conversion of common stock         $ 0 $ 0       $ 28 $ (28) $ 2 $ (2)        
Net loss (308,233)                             (308,233)  
Ending balance (in shares) at Dec. 31, 2023             40,841,834 218,524,009                  
Ending balance at Dec. 31, 2023 $ 914,777           $ 41 $ 219           1,713,560   (799,043)  
Ending balance (in shares) at Dec. 31, 2024 0                                
Ending balance at Dec. 31, 2024 $ 0                                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of common stock upon exercise of common stock options (in shares)               6,567,334                  
Issuance of common stock upon exercise of common stock options 9,712             $ 7           9,705      
Issuance of common stock upon vesting of restricted stock units (in shares)             1,663,016 4,176,480                  
Issuance of common stock upon vesting of restricted stock units 0           $ 2 $ 4           (6)      
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)               1,377,528                  
Issuance of common stock upon exercise of collaboration agreement warrants 14             $ 1           13      
Vested warrants related to the collaboration agreement 32,399                         32,399      
Stock-based compensation expense 138,767                         138,767      
Issuance of common stock under the employee stock purchase plan (in shares)             387,773                    
Issuance of common stock under the employee stock purchase plan 8,125                         8,125      
Shares withheld for tax withholding upon vesting of restricted stock units (in shares)             (139,996) (640,345)                  
Shares withheld for tax withholding upon vesting of restricted stock units (23,665)             $ (1)           (23,664)      
Conversion of common stock (in shares)                   46,203,674 (46,203,674)            
Conversion of common stock         0         $ 46 $ (46)            
Net loss (46,142)                             (46,142)  
Ending balance (in shares) at Dec. 31, 2024   88,956,301 183,801,332       88,956,301 183,801,332                  
Ending balance at Dec. 31, 2024 $ 1,033,987           $ 89 $ 184           1,878,899   (845,185)  
Ending balance (in shares) at Dec. 31, 2025 0                                
Ending balance at Dec. 31, 2025 $ 0                                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of common stock upon exercise of common stock options (in shares) 22,938,436             22,938,436                  
Issuance of common stock upon exercise of common stock options $ 2,203             $ 23           2,180      
Issuance of common stock upon vesting of restricted stock units (in shares)             4,535,044 2,627,219                  
Issuance of common stock upon vesting of restricted stock units 0           $ 4 $ 3           (7)      
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)               1,377,528                  
Issuance of common stock upon exercise of collaboration agreement warrants 15             $ 1           14      
Vested warrants related to the collaboration agreement 32,400                         32,400      
Stock-based compensation expense 166,447                         166,447      
Issuance of common stock under the employee stock purchase plan (in shares)             462,681                    
Issuance of common stock under the employee stock purchase plan 11,251                         11,251      
Shares withheld for tax withholding upon vesting of restricted stock units (in shares)             (291,690) (244,740)                  
Shares withheld for tax withholding upon vesting of restricted stock units (17,975)                         (17,975)      
Conversion of common stock (in shares)                   50,600,107 (50,600,107)            
Reclassification of redeemable common stock to Series B common stock       1,800,000                          
Conversion of common stock       $ 1,900,000 $ 0         $ 51 $ (51)       $ 136,900    
Net loss (31,768)                             (31,768)  
Ending balance (in shares) at Dec. 31, 2025   144,262,443 159,899,668       144,262,443 159,899,668                  
Ending balance at Dec. 31, 2025 $ 1,196,560           $ 144 $ 160           $ 2,073,209   $ (876,953)